Summary We investigated the effect of the flavonoid quercetin (Q) on the proliferation of the ovarian cancer cell line OVCA 433. Growth experiments demonstrated that Q exerted a reversible dose-dependent inhibition of cell proliferation in the range of concentrations between 10 nm and 10 M. Two other flavonoids tested, rutin and hesperidin, were ineffective in inhibiting cell growth. Cell cycle analysis showed that the growth inhibitory effect of Q was due to a blocking effect in the GO/GI phase. Using a whole cell assay with (6,7-3H) (Gabor, 1988) . Recently it has been reported that in the rat uterus and in the MCF-7 human breast cancer cell line the flavonoid quercetin (Q) inhibits cell growth and the uterotrophic response to oestradiol (Markaverich et al., 1988 Growth experiments Cells were plated in six-well flat bottom plates (Falcon 3046, Becton Dickinson, Lincoln Park, NJ, USA) at a concentration of I x 105 cells ml-' in MEM supplemented as above. After 24 h, the medium was replaced with fresh medium and Q (3,3',4',5,7-pentahydroxyflavone), rutin (3-rhamnosylglucoside of Q) and hesperidin (7-rhamnosylglucoside of Hesperitin) (3'-5-3-hydroxy-4-methoxy-flavanone) (Aldrich, Steinhein, FRG) were added from an absolute ethanol (Q) or DMSO stock solution (rutin, hesperidin). Control cells were treated with the same amount of vehicle alone. The final ethanol and DMSO concentration never exceeded 1 % (v/v) and 0.5% (v/v), in either control or treated samples, respectively.
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Summary We investigated the effect of the flavonoid quercetin (Q) on the proliferation of the ovarian cancer cell line OVCA 433. Growth experiments demonstrated that Q exerted a reversible dose-dependent inhibition of cell proliferation in the range of concentrations between 10 nm and 10 M. Two other flavonoids tested, rutin and hesperidin, were ineffective in inhibiting cell growth. Cell cycle analysis showed that the growth inhibitory effect of Q was due to a blocking effect in the GO/GI phase. Using a whole cell assay with (6,7-3H) oestradiol (3H-E2) as tracer we demonstrated that OVCA 433 cells contain type II oestrogen binding sites (type II EBS). Competition analysis showed that Q competed for 3H-E2 binding to type 11 EBS while both rutin and hesperidin did not. Appreciable amounts of type 11 EBS were also detected in seven primary ovarian tumours. Our results suggest that Q may regulate ovarian cancer cell growth through a mechanism involving a binding interaction with type II EBS. This mechanism could also be active in vivo since primary ovarian tumours contain type II EBS.
Flavonoids are a widely distributed class of natural substances with a variety of biological actions (Gabor, 1988) . Recently it has been reported that in the rat uterus and in the MCF-7 human breast cancer cell line the flavonoid quercetin (Q) inhibits cell growth and the uterotrophic response to oestradiol (Markaverich et al., 1988) . Although the mechanism of the antiproliferative activity of Q remains to be fully clarified, there is evidence suggesting that the action of this substance is probably mediated by its interaction with the so-called type II oestrogen binding site (type II EBS) (Markaverich et al., 1988 ). These sites originally described by Clark et al. (1978) in rat uterus, while displaying the same steroid and tissue specificity, are distinct from the 'true' oestrogen receptor (ER). They are reported to be present in higher concentrations than ER but to have a lower apparent affinity dissociation constant (KD 10-20 nM) for E2 than ER 
nM).
This possibility is supported by the demonstration that in rat uterus type II EBS are occupied in vivo by a flavonoidlike ligand with growth inhibitory activity (Markaverich et al., 1983a,b (Ranelletti et al., 1988) Figure 1 shows the effects of different flavonoids on OVCA 433 cell proliferation. Q produced a dose-dependent inhibition of cell growth while, even at the highest concentration tested (10 1M), rutin and hesperidin did not have any significant effect. When the time-dependent effect of Q was evaluated, it appeared that the antiproliferative action was already evident 24 h after the addition of the substance (Figure 2) .
The inhibitory effect of Q was not due to a non-specific cytotoxic action. In fact, cell viability which was more than 85% did not vary between control and treated cells, after the 3 day culture period. Furthermore, the inhibitory effect appears to be reversible since after the removal of Q, treated OVCA 433 cells regrew like untreated cells (Figure 3) .
To study further the antiproliferative activity of Q, we analysed the effect of this substance on the OVCA 433 cell cycle. As shown in Table I , the cytometric flow analysis revealed that Q produces an increase in the percentage of cells in the GO/GI phase of the cycle with a relative decrease of those in the S phase. (Figure 4b ) similar to that previously observed in other type II expressing systems (Ranelletti et al., 1988) . Since an accurate estimate of both the KD and the number of EBS cannot be made from a curvilinear Scatchard plot, these parameters were obtained from the saturation curve (Clark et al., 1978; Ranelletti et al., 1988) . For the experiment shown in Figure 4 the number of type II EBS calculated from the saturation curve at maximum binding is about 290,000 sites per cell. The KD determined from the 3H-E2 concentration required for half saturation is about 18 nM. In six similar experiments the number of sites per cell and the KD values were 320,900 ± 85,000 s.d. and 16 nM ± 3 s.d., respectively. Specificity experiments demonstrated that among different steroids tested only oestrogenic compounds inhibited the binding of 3H-E2 to type II EBS (Table II (Markaverich et al., 1981) .
In all cases Q displaced 3H-E2 from the type II EBS with a potency similar to that of DES, since the percentage of displacement are between 80% and 90% of the total bound. Four and three cases expressed ER and PR respectively (Table III) . However, although the number of specimens tested are very small, no correlation was found between type II EBS levels and ER and PR concentration. Furthermore, Q did not compete for 3H-E2 binding to ER (data not shown). Our data indicate that the flavonoid Q inhibits the growth of human ovarian cancer cells. This finding is in agreement with previous studies showing that Q has an antiproliferative action against human cancer cells in vitro (Markaverich et al., 1988; Yoshida et al., 1990) . The observation that a dietary supplement of Q inhibits the development of 7,12-dimethylbenzanthracene and N-nitrosomethylurea induced rat mammary cancer (Verma et al., 1988) strongly support the possibility that Q could also be active in vivo. In addition Q and certain related flavonoids may be inhibitors of experimental skin carcinogenesis (Nakadate et al., 1984; Nishino et al., 1984; Chang et al., 1985) . Although the mechanism of the antiproliferative activity of Q remains to be clarified, our data suggest that as in human breast cancer (Markaverich et al., 1988) and leukaemic cells (Larocca et al., 1990) , this flavonoid may regulate cell growth through a binding interaction with type II EBS. This hypothesis is supported by the following observations: (a) among the flavonoids tested only Q inhibits cell growth while both rutin and hesperidin, which do not bind to type II EBS are ineffective; (b) the cell growth inhibitory effect of Q is dosedependent and readily reversible upon removal of the substance indicating that Q does not act as a non-specific toxin randomly impairing the cellular metabolic machinery; (c) although bioflavonoids affect a variety of enzymes (Lang & Racker, 1974; Monaham et al., 1975; Kuriki & Racker, 1976; Bustamante & Pedersen, 1977; Graziani, 1977; Shosham & MacLennam, 1981; Graziani et al., 1983; Nishino et al., 1983 ) the concentrations eliciting these effects are in the range of 50-1I00 M. Conversely, Q both interacts with type II EBS and becomes effective as cell growth inhibitor at concentrations starting from 0.01 SAM.
Cytofluorimetric results indicate that the growth inhibitory effect of Q depends on a blocking action of cell transition from the GO/G I to the S phase of the cell cycle. This observation is in agreement with previous studies on human gastric cancer (Yoshida et al., 1990 ) and IM 9 lymphoblastoid cells (unpublished observation). Interestingly, primary ovarian tumours express appreciable amounts of type II EBS. Since type II EBS may be related to the control of cell growth it can be hypothesised that these binding sites may represent a biochemical parameter with possible prognostic significance.
The growth inhibitory properties of Q, together with the presence of type II EBS in primary ovarian cancer, suggest that this substance could be of some therapeutic potential.
Interestingly, a plasma concentration of 12 flM Q, which is similar to that effective in vitro in inhibiting ovarian cancer cell growth, was achieved following an intravenous injection of 100 mg without any apparent side effect (Gugler et al., 1975) . In addition to its own antiproliferative activity, it is worth noting that Q is able to enhance the antiproliferative effect of cis-diamminedichloroplatinum and nitrogen mustard in experimental tumour models (Hoffman et al., 1988) and in the human leukaemia cell line K 562 (Hoffman et al., 1989) .
